First mRNA Flu Vaccine Wins FDA Approval, but Moderna's Commercialization Outlook Remains Uncertain
Claire Weston
The FDA approved Moderna's mFlusiva — the world's first mRNA flu vaccine — for adults 50 and older; yet a paralyzed CDC advisory panel and political headwinds mean meaningful revenue may not arrive until the 2027-28 flu season.
What exactly did the FDA approve — and for whom?
The FDA granted full approval for adults aged 50 to 64, and accelerated approval for those 65 and older.
The accelerated pathway comes with a condition: Moderna must run a confirmatory study enrolling up to 800,000 participants over two flu seasons, comparing mFlusiva head-to-head with Fluzone High-Dose — the current preferred vaccine for seniors.
This means → for the 65-plus group, approval is "ship now, prove later." If the confirmatory trial disappoints, this portion of the approval can be withdrawn.
How well does it work — and what are the trade-offs?
In a pivotal trial of over 40,000 adults aged 50–64, mFlusiva showed roughly 26.6–27% relative efficacy over standard-dose flu shots. Against severe flu requiring a doctor visit or ER trip, efficacy reached 47.9%.
Side effects ran notably higher: nearly two-thirds reported injection-site pain, 45% reported fatigue, and 38% reported headaches — roughly double the rates in the control group.
Serious events linked to mFlusiva included one case of syncope, one episode of hypotension requiring a three-day hospital stay, and one case of pericardial myocarditis. In plain terms = better protection comes packaged with a markedly rougher post-shot experience — doctors and patients weigh both sides together.
Why was the approval process so turbulent?
In February, then-head of FDA's vaccine division Vinay Prasad refused to accept Moderna's application, arguing the company had compared mFlusiva against a suboptimal control vaccine — a move the industry considered highly unusual. Moderna president Stephen Hoge responded: "It felt like the rules of the game were changed after the game ended."
FDA Commissioner Marty Makary quickly reversed course, calling the rejection merely "part of a dialogue" between regulator and company. The review proceeded, and in June the FDA advisory committee voted unanimously to recommend approval.
This reflects a process that has moved beyond pure science: Health Secretary Robert F. Kennedy Jr. has long questioned mRNA technology, HHS canceled roughly $500 million in mRNA research contracts last year, and Prasad — a public Kennedy supporter — has since left the agency.
Does approval mean the vaccine can actually sell?
The CDC advisory committee — the body that issues national vaccine recommendations — is currently paralyzed by litigation. Kennedy replaced its members last year; a federal judge ruled most of his new appointees unqualified, and the panel has stalled.
In plain terms = without a CDC recommendation, doctors don't know whom to vaccinate, insurers don't know what to cover, and the vaccine can sit on shelves without moving.
Wall Street expects that because seasonal flu vaccine contracts are typically signed early in the year, mFlusiva's first meaningful revenue won't come until the 2027-28 flu season at the earliest.
What is the longer-term case for mRNA flu vaccines?
mRNA manufacturing can compress production timelines from roughly six months (traditional egg-based process) to two to three months, theoretically enabling a closer match to the season's circulating strains.
The mFlusiva approval also lays the groundwork for Moderna to revive its previously shelved combined COVID-flu mRNA vaccine application.
This means → the technology advantage is real, but converting it into market share hinges on when the CDC recommendation machinery comes back online. Until then, mRNA flu vaccines remain a story of "approved" rather than "scaling."
Content is for reference only, not financial advice.